 |
|
|
| |
HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough)
in PATIENTS presenting SIDE EFFECTS :
INTEREST of THERAPEUTIC DRUG MONITORING ?
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy
14-16 June 2017, Chicago, USA
C SOLAS1, S BREGIGEON2, O FAUCHER-ZAEGEL2, H LAROCHE2, V OBRY-ROGUET2, S QUARANTA3, C TAMALET4, B CANET2, B LACARELLE1,
I POIZOT-MARTIN2,5
1Aix Marseille Univ, APHM La Timone, Pharmacokinetics and Toxicology-Inserm U911-CRO2 SMARTc, Marseille, France; 2APHM Sainte-Marguerite, Clinical Immuno-Hematology, Marseille, France; 3AP-HM La Timone, Pharmacokinetics and Toxicology, Marseille. France; 4IHU Mediterranee Infection, Aix Marseille Univ, APHM, URMITE UM 63
CNRS 7278 IRD 198 INSERM 1095, Marseille, France; 5Aix Marseille Univ, Inserm U912-SESSTIM, Marseille, France
References:
(1): de Boer M. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 2016
(2): Hoffmann C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017
|
| |
|
|
|
|
|
